Lamivudine, Zidovudine, is a combination drug containing the active constituents lamivudine and Zidovudine. It is used to treat HIV–1 infection along with other medicines. The human immunodeficiency virus (HIV-1) targets and kills immune system cells; as a result, the body's capacity to fight off infections declines and, in severe cases, results in death. 

Patients with neutropenia (low white blood cells) or anemia (low red blood cells) should not use zidovudine or lamivudine. If you have any liver illness, including hepatitis B or C, kidney disease, or are overweight, let your doctor know. Lamivudine and zidovudine received separate approvals from the U.S. Food and Drug Administration (FDA). Lamivudine received FDA approval on November 17, 1995. Zidovudine received FDA approval on March 19, 1987.

 lamivudine and Zidovudine are used in the treatment of HIV–1 infection.

Lamivudine and Zidovudine capsules or tablets is taken orally. The medication is usually taken once a day, with or without food, as directed by your healthcare provider. Swallow the capsule or tablet whole without crushing or chewing it.

 lamivudine and Zidovudine can cause side effects such as nausea, vomiting, headache, diarrhea, fatigue, muscle pain, insomnia, rash, loss of appetite, abdominal pain, and joint pain. Although less common, these medications can also lead to serious side effects, such as severe allergic reactions, lactic acidosis, hepatotoxicity, blood disorders, and pancreatitis.

Lamivudine and zidovudine carry several important warnings. These include the risk of lactic acidosis and hepatomegaly with steatosis, hematologic toxicity, hepatotoxicity in individuals with pre-existing liver disease, immune reconstitution syndrome, potential drug interactions, pancreatitis, mitochondrial toxicity, immune system changes, hypersensitivity reactions, and considerations for use during pregnancy.

Inform your healthcare provider about all medications, including over-the-counter drugs and herbal supplements, to avoid potential drug interactions. Additionally, follow your healthcare provider's instructions regarding dosage and monitoring. Regularly attend check-ups to assess your response to the medications and address any concerns promptly.

Lamivudine and Zidovudine should not be used without consulting a healthcare provider. You should tell the healthcare provider if someone experiences unusual side effects while using this medicine. Inform the doctor if you have any prior liver disease, such as hepatitis B or C, kidney disease, or are overweight. If a woman is pregnant or breastfeeding, it is crucial to consult the doctor before using it. If you have any related questions about health, it is best to consult a healthcare provider.

1. KD Tripathi, Essentials of Medical Pharmacology, Antiviral drugs, 7th edition, 2013, 806 - 811.
2. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Antiretroviral agenteatment of HIV infection, 12th edition, 2011, 1632-1634.
3. Milpharm Limited, Electronic medicines compendium (EMC), [ Revised on September 2020] [ Accessed on 16th  May 2023], https://www.medicines.org.uk/emc/files/pil.2998.pdf
4. ViiV Healthcare, US Food and Drug Administration, [ Revised on September 2015] [ Accessed on 16th May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/...

The drug information on this page is different from medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.